Related Experiment Videos
Piroxicam, a novel anti-inflammatory agent
Arzneimittel-Forschung
|January 1, 1976
Summary
Piroxicam is a novel anti-inflammatory drug with high potency and a long plasma half-life, showing effectiveness comparable to indometacin. Its favorable profile, lacking CNS or cardiovascular effects, supports its clinical use.
Area of Science:
- Pharmacology
- Drug Discovery
Background:
- Piroxicam (CP-16 171) represents a new class of acidic anti-inflammatory agents.
- It is structurally distinct from existing drugs like indometacin, phenylbutazone, and naproxen.
Purpose of the Study:
- To characterize the pharmacokinetic and pharmacodynamic properties of piroxicam.
- To evaluate its anti-inflammatory potency and safety profile.
Main Methods:
- Pharmacokinetic studies were conducted to determine plasma half-life.
- Anti-inflammatory potency was assessed using the carrageenan rat paw edema model.
Main Results:
- Piroxicam demonstrated a longer plasma half-life compared to indometacin, phenylbutazone, and naproxen.
- Its potency in the carrageenan rat paw edema model was comparable to indometacin.
- Activity was independent of the adrenocorticoid system.
- No cardiovascular or central nervous system effects were observed.
Conclusions:
- Piroxicam exhibits significant anti-inflammatory properties.
- Its long half-life and favorable safety profile (no CNS/cardiovascular effects) make it a promising candidate for clinical trials.